Evotec has partnered Bristol-Myers Squibb to launch another Bridge programme, this time focusing on the universities of Birmingham, Dundee, Edinburgh and Nottingham.

The universities of Birmingham, Dundee, Edinburgh and Nottingham have joined forces with drug discovery firm Evotec and pharmaceutical firm Bristol-Myers Squibb to launch BeLab1407.
Equipped with $20m, BeLab1407 is the latest addition to Evotec’s international network of early-stage academic collaborations called Bridge – an acronym for Biomedical Research, Innovation and Development Generation Efficiency. It will focus on drug discovery.
Bridge was launched in 2016 through Lab282 at University of Oxford, with $16m of capital. The institution subsequently added Lab10x in 2019 to focus on digital therapeutics and data-driven drug discovery.
Adam Stoten, chief operating officer at tech transfer office Oxford University Innovation, spearheaded the initiative and last month revealed exclusively to GUV he was joining Evotec to expand the roster of partnerships further.
Existing partners also include Harvard University, Toronto Innovation Acceleration Partners, Fred Hutchinson Cancer Research Center and

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in